• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

沙特阿拉伯西部乳腺癌的免疫组织化学亚型(雌激素受体/孕激素受体/人表皮生长因子受体):我们处于什么水平?

Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?

作者信息

Khabaz Mohamad Nidal

机构信息

Department of Pathology, Faculty of Medicine, Rabigh Branch, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia E-mail :

出版信息

Asian Pac J Cancer Prev. 2014;15(19):8395-400. doi: 10.7314/apjcp.2014.15.19.8395.

DOI:10.7314/apjcp.2014.15.19.8395
PMID:25339035
Abstract

In Saudi Arabia, cancer of breast is ranked the most frequent neoplasm and second source of cancer death in the female population. Breast cancer (BC) fast diagnosis, prognosis and medication management necessitate, these days, immunohistochemistry (IHC) assessment of hormone receptors and HER2 expression profile. The present report defines the IHC profile of ER, PR and HER2 in Saudi female breast neoplasms of ductal and lobular types and associations ER, PR and HER2 expression patterns with various clinicopathological factors (age, type of tumor, size, laterality, histological grade, and involvement of axillaries lymph nodes). Ninety nine cases of breast tumors were recruited from the pathology department archive of King Abdulaziz University Hospital, Kingdom of Saudi Arabia. ER, PR and HER2 expression was assessed using IHC staining. Ductal carcinomas with a variety of histological grades constituted 88 (88.8%) of total cases. Seventy four (77.8%), 59 (62.1%), and 35 (36.8%) of ductal carcinomas showed positive staining for ER, PR and HER2, in that order. Remaining breast cancer cases were four (4%) lobular carcinomas and two (2%) mixed form of ductal and lobular types, which were ER+, PR+, and HER2-. Breast cancer expression pattern of ER, PR and HER2 in Saudi female is different from that of Tunisian and Jordanian female populations and closer to the expression pattern of Egyptian, Lebanese, Iraqi and western country females. Furthermore, the present study found two IHC patterns of breast cancer ER+/PR-/HER2+ (5%) and ER+/PR-/HER2- (11.1%), which had not been reported in other Arabic studies. Thus the rates of IHC expression patterns in breast cancer show some variation among Arabic female populations.

摘要

在沙特阿拉伯,乳腺癌是女性中最常见的肿瘤,也是癌症死亡的第二大原因。如今,乳腺癌(BC)的快速诊断、预后和药物管理需要对激素受体和HER2表达谱进行免疫组织化学(IHC)评估。本报告定义了沙特女性导管型和小叶型乳腺肿瘤中ER、PR和HER2的IHC谱,并将ER、PR和HER2表达模式与各种临床病理因素(年龄、肿瘤类型、大小、侧别、组织学分级和腋窝淋巴结受累情况)相关联。从沙特阿拉伯王国阿卜杜勒阿齐兹国王大学医院病理科档案中收集了99例乳腺肿瘤病例。使用IHC染色评估ER、PR和HER2的表达。各种组织学分级的导管癌占总病例的88例(88.8%)。导管癌中分别有74例(77.8%)、59例(62.1%)和35例(36.8%)依次显示ER、PR和HER2阳性染色。其余乳腺癌病例为4例(4%)小叶癌和2例(2%)导管和小叶混合型,均为ER+、PR+、HER2 -。沙特女性乳腺癌ER、PR和HER2的表达模式与突尼斯和约旦女性人群不同,更接近埃及、黎巴嫩、伊拉克和西方国家女性的表达模式。此外,本研究发现了两种乳腺癌的IHC模式ER+/PR -/HER2+(5%)和ER+/PR -/HER2 -(11.1%),这在其他阿拉伯研究中尚未报道。因此,乳腺癌IHC表达模式的发生率在阿拉伯女性人群中存在一些差异。

相似文献

1
Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?沙特阿拉伯西部乳腺癌的免疫组织化学亚型(雌激素受体/孕激素受体/人表皮生长因子受体):我们处于什么水平?
Asian Pac J Cancer Prev. 2014;15(19):8395-400. doi: 10.7314/apjcp.2014.15.19.8395.
2
Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.土耳其东南部不同种族乳腺癌患者的激素受体及HER2状态
J BUON. 2013 Jul-Sep;18(3):619-22.
3
Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.乳腺癌中Ki67的表达。沙特患者中与预后标志物及临床病理参数的相关性
Saudi Med J. 2016 Feb;37(2):137-41. doi: 10.15537/smj.2016.2.12285.
4
Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.原发性乳腺癌新辅助化疗前后雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER2)的表达:单机构经验
Int J Clin Exp Pathol. 2012;5(6):530-6. Epub 2012 Jul 29.
5
Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.撒哈拉以南非洲地区的乳腺癌真的受体缺乏吗?肯尼亚乳腺癌中雌激素受体/孕激素受体/人表皮生长因子受体2的患病率。
Breast. 2014 Oct;23(5):591-6. doi: 10.1016/j.breast.2014.06.006. Epub 2014 Jul 7.
6
Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.由雌激素受体/孕激素受体(ER/PR)和人表皮生长因子受体2(HER2)状态定义的乳腺癌分子亚型:与科特迪瓦患者临床病理参数的相关性
Asian Pac J Cancer Prev. 2016;17(4):1973-8. doi: 10.7314/apjcp.2016.17.4.1973.
7
Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.约旦乳腺癌病例中激素受体及人表皮生长因子受体2/neu的患病率
Pathol Oncol Res. 2006;12(2):83-6. doi: 10.1007/BF02893449. Epub 2006 Jun 24.
8
Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)的协同表达在低分化乳腺癌中定义了不同的预后亚型。
Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.
9
Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.土耳其患者乳腺癌新辅助化疗的回顾性分析。
Asian Pac J Cancer Prev. 2012;13(8):4119-23.
10
The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.原发性乳腺癌与同期腋窝淋巴结转移中激素受体和 HER2 状态的病例对照比较。
Asian Pac J Cancer Prev. 2020 Jun 1;21(6):1559-1565. doi: 10.31557/APJCP.2020.21.6.1559.

引用本文的文献

1
Contralateral breast cancer in patients carrying mutations in the BRCA1∕2 gene.携带BRCA1∕2基因突变的患者发生的对侧乳腺癌。
Rom J Morphol Embryol. 2025 Jan-Mar;66(1):111-118. doi: 10.47162/RJME.66.1.10.
2
Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia.乳腺癌免疫组织化学亚型在埃塞俄比亚四个地区的分布。
Front Endocrinol (Lausanne). 2023 Nov 9;14:1250189. doi: 10.3389/fendo.2023.1250189. eCollection 2023.
3
Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years.
多年来约旦乳腺癌患者中雌激素受体/孕激素受体/人表皮生长因子受体 2 阳性率的变化趋势。
JCO Glob Oncol. 2022 Mar;8:e2100359. doi: 10.1200/GO.21.00359.
4
Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients.三阴性与三阳性及HER2型伊拉克乳腺癌患者临床病理表现的比较
Open Access Maced J Med Sci. 2019 Oct 14;7(21):3534-3539. doi: 10.3889/oamjms.2019.808. eCollection 2019 Nov 15.
5
First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.摩洛哥东部地区乳腺癌分子亚型及其临床病理特征的首次报告:2260例病例系列
BMC Womens Health. 2017 Jan 9;17(1):3. doi: 10.1186/s12905-016-0361-z.
6
Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer.TCH/TEC新辅助化疗治疗HER-2过表达乳腺癌的疗效
Oncol Lett. 2015 Apr;9(4):1922-1926. doi: 10.3892/ol.2015.2912. Epub 2015 Jan 28.